Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy	autoimmune disease, immune system disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease	Recruiting	Phase 2	2026-09-17		NCT07103746

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Autoimmunity Centers of Excellence	2
National Institute of Allergy and Infectious Diseases (NIAID)	402
Rho Federal Systems Division, Inc.	12
TG Therapeutics	1

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Emory University School of Medicine: Division of Rheumatology	Atlanta	United States	1
Johns Hopkins Hospital: Division of Rheumatology	Baltimore	United States	1
Mayo Clinic: Division of Rheumatology	Rochester	United States	1
Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology	Great Neck	United States	2
University of Alabama at Birmingham School of Medicine: Division of Clinical Immunology & Rheumatology	Birmingham	United States	1
University of Chicago, Department of Medicine: Rheumatology	Chicago	United States	2
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology	Pittsburgh	United States	1
University of Texas - Houston	Houston	United States	6